Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CI 941

Known as: CI-941, CI941 
 
National Institutes of Health

Related topics

Related topics

3 relations
BiantrazoleDuP 941

Broader (1)

losoxantrone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin
SummaryThe MCF-7 cell S9 fraction and whole MCF-7 cells can mediate one-electron-redox cycling of doxorubicin, giving rise to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
1996
1996
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
The reversing effect of p-glycoprotein (Pgp) inhibitors on the multidrug resistance (MDR) phenotype is well established in a… Expand
1993
1993
Detection and identification of human urinary metabolites of biantrazole (CI-941).
The anthrapyrazole derivative biantrazole (7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2- hydroxyethyl)amino]ethyl]amino… Expand
1992
1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.
The development of new drugs in early clinical trials is currently based upon the results of preclinical antitumour and toxicity… Expand
1992
1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
The pharmacokinetics of the anthrapyrazole CI-941 has been investigated in conjunction with the Phase I evaluation of the drug… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
1991
Highly Cited
1991
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone… Expand
Review
1991
Review
1991
Anthrapyrazoles: true successors to the anthracyclines?
  • I. Judson
  • Anti-cancer drugs
  • 1991
    • Corpus ID: 8473267
The anthrapyrazoles are a new class of intercalating agents which were synthesized in order to reduce the potential for free… Expand
1989
1989
Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.
This assay has facilitated the accurate determination of the pharmacokinetics of the drug in patients treated at the phase I… Expand
1987
1987
The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro.
The anthrapyrazole CI941 is one of a new series of DNA complexing drugs which displays high level broad spectrum antitumour… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE